Recent Press Releases

Scientific Clinical | Nanobiotix announces Fast Track designation granted by U.S. FDA for investigation of first-in-class NBTXR3 in Head and Neck cancer
Scientific Clinical | Nanobiotix announces plan for global phase III Head and Neck cancer registration trial along with overall development update
Corporate | Nanobiotix receives the 2019 Prix Galien award for first-in-class Hensify

ALL NANOBIOTIX PRESS RELEASE

Overview_News_1


NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care :

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.


    See more

    Events

    April 24-29, 2020

    AACR 2020

    More info
    February 27-29

    Multidisciplinary Head & Neck cancer Symposium

    More info

    JOIN US


    "Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life."

    Anne-Juliette Hermant
    Chief People Officer
     

    Download our latest
    Corporate Presentation

     
    English